A Belgian start-up ophthalmology company, Amakem NV, has raised €18 million in a Series A round to progress its lead product for glaucoma into a clinical proof-of-concept study. The round was led by Forbion Capital Partners. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals